Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 3137Neoplasms 2472Carcinoma, Non-Small-Cell Lung 1886Prostatic Neoplasms 1635Colorectal Neoplasms 1435Lung Neoplasms 1308Multiple Myeloma 939Neoplasm Metastasis 928Leukemia, Myeloid, Acute 884Pancreatic Neoplasms 856Ovarian Neoplasms 810Melanoma 791Carcinoma, Hepatocellular 742Stomach Neoplasms 648Brain Neoplasms 641Recurrence 640Squamous Cell Carcinoma of Head and Neck 639Head and Neck Neoplasms 612Glioblastoma 573Lymphoma 550Uterine Cervical Neoplasms 545Triple Negative Breast Neoplasms 513Precursor Cell Lymphoblastic Leukemia-Lymphoma 509Carcinoma, Renal Cell 504Hematologic Neoplasms 466Endometrial Neoplasms 466Urinary Bladder Neoplasms 462Colonic Neoplasms 446Lymphoma, Non-Hodgkin 439Sarcoma 436

Interventions

Sodium Chloride 1BNT162 Vaccine 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Severe Acute Respiratory Syndrome × 1 year × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡